



## **iTeos Therapeutics to Present at UBS Global Healthcare Conference**

May 7, 2019

**Gosselies, Belgium and Cambridge, MA – May 13, 2019** – iTeos Therapeutics SA, a privately-held biotechnology company developing novel cancer immunotherapies, today announced that Michel Detheux, Ph.D., President and Chief Executive Officer of iTeos, will present at the UBS Global Healthcare Conference on Monday, May 20, 2019 at 11:30 a.m. ET in New York, NY.

### **About iTeos Therapeutics iTeos**

Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to transforming the lives of persons living with cancer by designing and developing next generation immunotherapies. The Company's lead program, EOS100850, is an adenosine A<sub>2A</sub> receptor antagonist currently in a Phase 1/1b study. A second program, a fully human ADCC-enabling anti-TIGIT antibody (EOS884448), is expected to enter the clinic in the second half of 2019. Based in Gosselies, Belgium and Cambridge, MA, iTeos Therapeutics was founded through the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute (Université Catholique de Louvain). In 2018, the Company completed a \$75 million (€64 million) Series B financing led by MPM Capital, along with new investors HBM Partners, 6 Dimensions Capital and Curative Ventures. Previous investors, including Fund +, VIVES II and SRIW, as well as SFPI, also participated in this funding round. For more information, please visit [www.iteostherapeutics.com](http://www.iteostherapeutics.com).

### **For further information, please contact:**

Michel Detheux, CEO  
iTeos Therapeutics  
[info@iteostherapeutics.com](mailto:info@iteostherapeutics.com)

Amber Fennell, Mathew Neal, Sukaina Virji, and Catherine London  
Consilium Strategic Communications  
+44 203 709 5700  
[iteos@consilium-comms.com](mailto:iteos@consilium-comms.com)

Sarah McCabe  
Stern Investor Relations, Inc.  
+ 1 212 362 1200  
[iTeos@sternir.com](mailto:iTeos@sternir.com)